MétaCan
Menu
Back to cohort
Record W3126915654 · doi:10.1200/jco.20.03420

Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer

2021· article· en· W3126915654 on OpenAlexaff
Sonali M. Smith, KERRI WACHTER, Howard A. Burris, Richard L. Schilsky, Daniel J. George, Douglas E. Peterson, Melissa L. Johnson, Merry Jennifer Markham, Kathryn F. Mileham, Muhammad Shaalan Beg, Johanna C. Bendell, Robert Dreicer, Vicki L. Keedy, Randall J. Kimple, Miriam A. Knoll, Noelle K. LoConte, Helen Mackay, Jane Meisel, Timothy J. Moynihan, Daniel A. Mulrooney, Therese M. Mulvey, Olatoyosi Odenike, Nathan A. Pennell, Katherine E. Reeder‐Hayes, Cardinale B. Smith, Ryan J. Sullivan, Robert G. Uzzo

Bibliographic record

VenueJournal of Clinical Oncology · 2021
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer Genomics and Diagnostics
Canadian institutionsHealth Sciences CentreSunnybrook Health Science Centre
FundersNational Institute for Health and Care ResearchCancer Research UKBowel Cancer UK
KeywordsMedicineCancerOncologyInternal medicine

Abstract

fetched live from OpenAlex

Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer highlights the most important clinical research advances of the past year and identifies priority areas where ASCO believes research efforts should be focused moving forward.This year's report also discusses the critical issue of health equity in cancer research and solutions to ensure that every patient with cancer, everywhere, can access the latest advances. Achieving Equity in Cancer ResearchOverall cancer mortality has decreased in the United States 1 thanks to tremendous progress in cancer prevention, early detection, and treatment-underpinned by decades of research progress.2 Unfortunately, not all individuals with cancer have benefited equitably from this success, as Blacks, 3 patients living in rural areas, 4 populations with lower income and education levels, 5 and others continue to experience lower survival and higher mortality rates for many cancers.As clinicians, we are committed to providing evidenced-based, high-quality cancer care to every patient, every day, everywhere.But, if clinical trials don't represent the individuals we treat, including those from racial, ethnic, and other minority populations, the state of science suffers, and patients with life-threatening conditions may not receive the best-perhaps only-treatment option for their condition.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.011
metaresearch head score (Gemma)0.012
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.076
Threshold uncertainty score0.254

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0110.012
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0030.002
Science and technology studies0.0020.001
Scholarly communication0.0100.004
Open science0.0020.006
Research integrity0.0120.012
Insufficient payload (model declined to judge)0.0760.048

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.069
GPT teacher head0.497
Teacher spread0.428 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations97
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicCancer Genomics and DiagnosticsFrench-language works237,207